ANTH — Anthera Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$8.09m
Annual income statement for Anthera Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2013 December 31st | 2014 December 31st | 2015 December 31st | 2016 December 31st | 2017 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 3.19 | 0.145 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 28.2 | 28.5 | 38.4 | 57.3 | 36.4 |
| Operating Profit | -28.2 | -28.5 | -35.2 | -57.2 | -36.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -30.9 | -29.6 | -35.2 | -55.5 | -26.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -30.9 | -29.6 | -35.2 | -55.5 | -26.9 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -30.9 | -29.6 | -35.2 | -55.5 | -26.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -30.9 | -29.6 | -35.2 | -66.4 | -29.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13.5 | -10.9 | -7.91 | -12.9 | -2.86 |
| Dividends per Share |